ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

CUVL // Clinuvel Pharmaceuticals Limited

FA <GO> NASDAQ RQD COCKPIT → CIK 0001290877 ↗
Industrials • Miscellaneous
$5.15 ▲ +0.08 (+1.58%)
MKT CAP: $257.8M • VOL: 8.2K
CUVL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
LINE ITEM (USD / %)
FY 2025
FILED 2025-06-30
FY 2024
FILED 2024-06-30
Revenue (Total Sales) $61.1M $57.9M
YoY Revenue Growth % +5.5% —
Gross Profit $49.6M $47.2M
Gross Margin % 81.2% 81.5%
Research & Development (R&D) — —
Operating Income (EBIT) $26.5M $28.5M
Operating Margin % 43.4% 49.3%
Net Income (GAAP) $23.1M $23.3M
EBITDA (Normalized) $26.7M $31.4M
Diluted EPS ($/sh) — —
Operating Cash Flow (OCF) $27.3M $23.8M
Capital Expenditures (CapEx) $190.6K $3.7M
Free Cash Flow (FCF) $27.1M $20.1M
FCF Margin % 44.3% 34.7%
Return on Invested Capital (ROIC %) — —
Cash & Short-Term Equivalents — —
Total Debt (Short + Long Term) — —
Total Stockholders' Equity — —